Dual Integrated Attention Program (DAIP) in People With Severe Dual Diagnosis

NCT04442776 | Unknown

• 2 other identifiers: Study DAIPESTUDIO PAI-D
• Study Type: interventional
• Target: 86
• Locations: 0 countries
• Sites: N/A

Brief Summary

Aim: validate a Dual Integrated Attention Program (D-AIP) for mental health nursing in people with Severe Dual Diagnosis admitted to a psychiatric hospitalization unit Design: Randomized Controlled Trial. Population: Inpatients with dual diagnosis.

Conditions

Diagnosis, Dual (Psychiatry)

Keywords

Psychiatric Dual Diagnosis; Integrated Attention; Program

Outcome Measures

Primary Outcomes (6)

• Stages of Change Readiness

  Assessed by Questionnaire SOCRATES 8D

  12 months

• Insight

  Assessed by Scale Unawareness of Mental Disorders (SUMD)

  12 months

• Medication Adherence

  Assessed by Medication Adherence Scale (MMAS-8)

  12 months

• Therapeutic Alliance

  Assessed by Working Alliance Inventory in patients and therapist (WAI-P and WAI-T)

  2-3 months

• Anxiety

  Assessed by Hamilton Anxiety Rating Scale (HARS)

  12 months

• Hopelessness

  Assessed by Hopelessness Scale (HS)

  12 months

Secondary Outcomes (4)

• Containments methods

  2-3 months

• Drug use change

  12 months

• Hospital readmissions

  12 months

• Dual diagnosis knowledge

  12 months

Study Arms (2)

Intervention group

EXPERIMENTAL

The intervention group will complete the Dual Integrated Attention Program (D-AIP) The D-AIP will consist on 6 individualized sessions with the psychiatric inpatients, and during follow-up up to one year after discharge in which 4 individual sessions and 3 telephone contacts will be made.

Behavioral: D-AIP

Control group

NO INTERVENTION

The control group will complete the usual treatment. One session per day voluntary during admission and discharge, nursing consultations only to put injectable medication

Interventions

D-AIP BEHAVIORAL

Intervention on change motivation, insight, medication adherence, drug consumption abstinence or reduction, therapeutic alliance, hopelessness and anxiety

Intervention group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Inpatients diagnosed with some serious mental illness of the following:
• Inpatients with diagnosis of schizophrenia
• Inpatients with diagnosis schizoaffective disorder
• Inpatients with diagnosis bipolar disorder types I
• Inpatients with diagnosis bipolar disorder types II
• Consumption of addictive substances

You may not qualify if:

• Intellectually Disabled

Sponsors & Collaborators

• Cardenal Herrera University: lead

MeSH Terms

Conditions

Disease

Condition Hierarchy (Ancestors)

Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Montse Cañabate, Dra.

  Cardenal Herrera University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Montse Cañabate, Dra.

CONTACT

+34-601-209-435; montserrat.canabate@uchceu.es

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Model Details: Randomized Controlled Trial (Parallel Assignment)

Study Record Dates

• First Submitted: February 20, 2020
• First Posted: June 23, 2020
• Study Start: September 1, 2020
• Primary Completion: April 1, 2021
• Study Completion: May 1, 2023
• Last Updated: June 23, 2020

Record last verified: 2020-06